PTO/SB/08A (08-00) Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE s, no persons are required to respond to a collection of information unless it contains a valid OMB control number Under the Papery

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 1 of 6

Com	plete if Known	
Application Number	10/635,928	
Filing Date	August 6, 2003	
First Nam d Invent r	Venkataraman	
Group Art Unit		
Examiner Name		
Attorney Docket Number	52761/286146	

				U.S. PATENT DOCUMENT	S	
Examiner Initials	Cite No.1		nt d Code ² known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pp., Columns, Lines, Where Relevant Passages or Relevant Figures Appear
W.C+	1.	5,494,678		Paradissis, et al.	02-27-1996	
1	2.	5,563,126		Allen, et al.	10-08-1996	
	3.	5,795,873		Allen	08-18-1998	
	4.	5,801,161		Merkus	09-01-1998	
	5.	5,932,624		Herbert	08-03-1999	
	6.	5,962,048		Register	10-05-1999	
	7.	6,039,978		Bangs, et al.	03-21-2000	
	8.	6,048,846		Cochran	04-11-2000	
	9.	6,121,249		Weissman. et al.	09-19-2000	
	10.	6,127,370		Smith, et al.	10-03-2000	
	11.	6,207,651	B1	Allen, et al.	03-27-2001	
T	12.	6,299,896	B1	Cooper, et al.	10-09-2001	
	13.	6,323,188	B1	Weissman	11-27-2001	
	14.	6,361,800	B1	Cooper, et al.	03-26-2002	- W
	15.	6,369,041	B2	Horrobin, et al.	04-09-2002	*****
	16.	6,479,545	B1	Levinson, et al.	11/12-2002	
	17.	6,528,496	B1	Allen, et al.	03-04-2003	
	18.	2002/0010148	A1	Horrobin, et al.	01-24-2002	
	19.	2002/0136711	A1	Cochran	09-26-2002	
	20.	2002/0146463	A1	Clayton	10-10-2002	
	21.	2003/0049352	A1	Mehansho, et al.	03-13-2003	
m·e.4	22.	2003/017136 (Abstract)	A1	Cruz, et al.	01-23-2003	

				FORE	IGN PATENT DOCUMENTS			
	Cite		Foreign Patent Docume	ent	Name of Boards	Date of Publication	Pp., Columns, Lines,	T
Examiner Initials		Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document Relevant Passa	Where Relevant Passages or Relevant Figures Appear	14
W·C·H	23.	EP	0366480 (Abstract)	B1	Bar Ilan University	08-24-1994		
	24.	wo	96/11009 (Abstract)	A1	UK	04-18-1996		
	25.	wo	98/01157 (Abstract)	A1	WWK Trust, Worsley, Andrew Peter	01-15-1998		
	26.	wo	2000/056295 (Abstract)	A2	Kilgowan Limited	09-28-2000		
1	27.	wo	2001/056609 (Abstract)	A1	Germany	08-09-2001		
M.C.H	28.	wo	2002/087593 (Abstract)	A1	Cobalz Limited	11-07-2002		

Examiner Signature	100	Date Considered	4/6/04	_
				_

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached. ATLLIB02 138545.2

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

tk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paper Substitute for Form 1449/A/PTO

Sheet 2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary of 6

Complete if Known Application Numb r 10/635,928 Filing Dat August 6, 2003 **First Named Inventor** Venkataraman Group Art Unit **Examiner Name** Attorney Docket Number 52761/286146

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examine f Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	29.	ALTURA, BURTON M. and ALTURA, BELLA T., "Magnesium and Cardiovascular Biology: An	
۸. ۵.		Important Link Between Cardiovascular Risk Factors and Atherogenesis," Cellular and Molecular	
W (#		Biology Research, 1995, pp. 347-359, Vol. 41, No. 5.	
1	30.	ANDERSSON, H.C., et al., "Long-Term Outcome in Treated Combined Methylmalonic Acidemia	
		and Homocystinemia," Genet Med, May-June 1999, pp. 146-150. (Abstract)	
	31.	APPEL, LAWRENCE, J., et al., "A Clinical Trial of the Effects of Dietary Patterns on Blood	
		Pressure," N. Engl. J. Med, April 17, 1997, pp. 1117-1124, Vol. 336, No. 16.	
	32.	BASU, TAPAN K. and MANN, SARABJIT, "Vitamin B-6 Normalizes the Altered Sulfur Amino Acid	
.		Status of Rats Fed Diets Containing Pharmacological Levels of Niacin Without Reducing Niacin's	
		Hypolipidemic Effects," J. Nutr., 1997, pp.117-121, Vol. 127.	
1	33.	BLOOM, O. JOSH, et al., "Do Antioxidants (Vitamins C, E) Improve Outcomes in Patients With	
		Coronary Artery Disease?" J. Fam. Prac., November 2002, p. 978, Vol. 51, No. 11.	
	34.	BLUMBERG, A., et al., "Vitamin Nutrition in Patients on Continuous Ambulatory Peritoneal	
		Dialysis (CAPD)," Clin Nephrol, November 1983, pp. 244-250, Vol. 20, No. 5. (Abstract)	
	35.	BOUSHEY, CAROL J., et al., "A Quantitative Assessment of Plasma Homocysteine as a Risk	1
		Factor for Vascular Disease," JAMA, October 4, 1995, pp. 1049-1057, Vol. 274, No. 13.	
1	36.	BRATTSTROM, L. E., et al., "Folic Acid - An Innocuous Means to Reduce Plasma	
		Homocysteine," Scand J. Clin. Lab Invest., 1998, pp. 215-221, Vol. 48.	
	37.	BRATTSTROM, LARS E., et al., "Folic Acid Responsive Postmenopausal Homocysteinemia,	1
		Metabolism," November 1985, pp. 1073-1077, Vol. 34, No. 11.	
	38.	BRATTSTROM, LARS, et al., "Impaired Homocysteine Metabolism in Early-Onset Cerebral and	
		Peripheral Occlusive Arterial Disease," Atherosclerosis, 1990, pp. 51-60, Vol. 81.	
	39.	CAMPBELL, BRUCE G., et al., "Do Calcium Supplements Prevent Postmenopausal Osteoporotic	
1		Fractures?" J of Fam Prac., March 2003, pp. 236-237, Vol. 52, No. 3.	
14	40.	CHAMBERS, JOHN C., et al., "Improved Vascular Endothelial Function After Oral B Vitamins,"	1
w (+1		Circulation, Nov. 14, 2000, pp. 2479-2483, Vol. 102.	

Examiner Signature Date Considered 4/6/04	104
---	-----

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

995, no persons are required to respond to a collection of information unless it contains a valid OMB control number SEP 1 1 2003 work Reduction Act

Substitute for Form 1449/A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary of 6

Complete if Known **Application Number** 10/635,928 Filing Dat August 6, 2003 First Named Inventor Venkataraman **Group Art Unit Examiner Name** Attorney Docket Number 52761/286146

			OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Exam r Initia	1	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	_	41.	CHAN, P., et al., "Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy	
1.			of Vitamin B Complex in the Treatment of Nocturnal Leg Cramps in Elderly Patients with	
Mo	+#		Hypertension," J Clin Pharmacol., 1998, pp. 1151-1154, Vol. 38, No. 12. (Abstract)	
Πİ		42.	DOSHI, SAGAR N., et al., "Folic Acid Improves Endothelial Function in Coronary Artery Disease	
1 /			via Mechanisms Largely Independent of Homocysteine Lowering," Circulation, January 1/8, 2002,	
11			pp. 23-26, Vol. 102.	
		43.	DUDMAN, NICHOLAS P. B., et al., "Homocysteinemia: Depressed Plasma Serine Levels,"	
admillion and			Metabolism, February 1987, pp. 198-201, Vol. 36, No. 2.	
		44.	ELIAN, et al., "Hydroxocobalamin Reduces Hyperhomocysteinemia in End-Stage Renal Disease,"	
			Metabolism, July 2002, pp. 881-886, Vol. 51. (Abstract)	
		45.	FANG, JAMES C., et al., "Effect of Vitamins C and E on Progression of Transplant-Associated	<u> </u>
			Arteriosclerosis: A Randomised Trial," The Lancet, March 30, 2002, pp. 1108-1113, Vol. 359.	
		46.	FRANKEN, D.G., et al., "Effect of Various Regimens of Vitamin B ₆ , and Folic Acid on Mild	
			Hyperhomocysteinaemia in Vascular Patients," J. Inher. Metab. Dis., 1994, pp. 159-162, Vol. 17.	
		47.	GABY, A. R., "Intravenous Nutrient Therapy: The Myers' Cocktail," Altern Med Rev, Oct. 2002,	1
	- {		pp. 389-403.	
		48.	GARG, REKKA, et al., "Niacin Treatment Increases Plasma Homocyst(e)ine Levels," Am Heart J.,	
			December 1999, pp 1082-1087, Vol. 138, No.6, Part 1.	
		49.	GOTTFRIES, C. G., "Pharmacological Treatment Strategies in Alzheimer Type Dementia," Eur	
			Neuropsychopharmacol, Nov. 1990, pp. 1-5. (Abstract)	
		50.	HAIDARI, MEHRAN, et al., "Enhanced Susceptibility to Oxidation and Diminished Vitamin E	
			Content of LDL from Patients with Stable Coronary Artery Disease," Clinical Chemistry, 2001, pp.	
1	-		1234-1240, Vol. 47, No.7.	
-	7	51.	HARPEY, JEAN-PAUL, et al., "Homocystinuria Caused by 5,10-Methylenetetrahydrofolate	
٨ ٨			Reductase Deficiency: A Case in an Infant Responding to Methionine, Folinic Acid, Pyridoxine,	
/h·(·	·H		and Vitamin B ₁₂ Therapy," J Pediatrics, February 1981, pp. 275-278, Vol. 98, No. 2.	

Examiner Signature	4	Date Considered	4/6/1	04

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a unlife OMB account. no persons are required Under the Paperwork

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary

Sheet 4 of 6

to respond to a collection of informa-	HIGH UNITESS IT CONTENTS & VAIID CONTENT HUMBER
Com	pl te if Known
Application Numb r	10/635,928
Filing Dat	August 6, 2003
First Named Inv ntor	Venkataraman
Group Art Unit	
Examiner Name	
Attorney Docket Number	52761/286146

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examine f Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	. T²
	52.	HEINECKE, JAY W., "Is the Emperor Wearing Clothes?" Arterioscler Thromb Vasc Biol., August	
H.3M		2001, pp. 1261-1264, Vol. 21.	
	53.	HEINONEN, O.P., et al., "The Effect of Vitamin E and Beta Carotene on the Incidence of Lung	
		Cancer and Other Cancers in Male Smokers," TN Engl J Med, April 14, 1994, pp. 1029-1035, Vol.	
		330, No. 15.	<u> </u>
	54.	HENKIN, YAAKOV, et al., "Niacin Revisited: Clinical Observations on an Important But	
		Underutilized Drug," Am J Med, September 1991, pp. 239-246, Vol. 91.	
	55.	HERBERT, V., "The Inhibition and Promotion of Cancers by Folic Acid, Vitamin B ₁₂ , and their	
.		Antagonists," American Chemical Society (ACS Symposium series), 1985, pp. 32-36, Vol. 277.	
	56.	KAUL, NALINI, et al., "α-Tocopherol and Atherosclerosis," E.B.M., 2001, pp. 5-12, Vol. 226.	
	57.	KLERK, M., "Effect of Homocysteine Reduction by B-Vitamin Supplementation on Markers of	
		Clotting Activation," Thromb Haemost, Aug. 2002, pp. 230-235, Vol. 88.	
	58.	LIAO, FANGZI, et al., "Is Low Magnesium Concentration a Risk Factor For Coronary Heart	
		Disease? The Atherosclerosis Risk in Communities (ARIC) Study," Am Heart J, September 1998,	
		pp. 480-490, Vol. 136, No. 3.	
	59.	MARCHESONI, D., et al., "Menopause Rather than Estrogen Modifies Plasma Homocysteine	1
		Levels," International Journal of Gynecology and Obstetrics, 2003, pp. 293-297, Vol. 81.	
	60.	MASON, JB and MILLER, J.W., "The Effects of Vitamins B12, B6, and Folate on Blood	
		Homocysteine Levels," Ann NY Acad Sci., Sept. 30, 1992, pp. 197-203.	
	61.	NILSSON, K., et al., "Treatment of Cobalamin Deficiency in Dementia, Evaluated Clinically and	
		With Cerebral Blood Flow Measurements," Aging (Milano), June 2000, pp. 199-207, Vol. 12.	
	62.	OLSZEWSKI, ANDRZEJ J., et al., "Reduction of Plasma Lipid and Homocysteine Levels by	
		Pyridoxine, Folate, Cobalamin, Choline, Riboflavin, and Troxerutin in Atherosclerosis,"	
		Atherosclersis, 1989, pp. 1-6, Vol. 75.	
1	63.	ROSSI, A., et al., "Early-Onset Combined Methymalonic Aciduria and Homocystinuria:	
MI		Neuroradiologic Findings," Am J. Neuroradiol, March 2001, pp. 554-563, Vol. 22.	

Examiner Signature	Ph	Date Considered	4	16/04

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
no persons are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwo

Substitute for Form 1449/A/PTO

Sheet 5

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary of 6

Complete if Known **Application Number** 10/635,928 August 6, 2003 **Filing Date** First Named Inventor Venkataraman **Group Art Unit Examiner Name** Attorney Docket Number 52761/286146

	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	L ₅
64.	ROSSOUW, JACQUES E., et al., "Risks and Benefits of Estrogen Plus Progestin in Healthy	
	Postmenopausal Women" JAMA, July 17, 2002, pp. 321-333, Vol. 288, No. 3.	
65.	SCHNYDER, GUIDO, et al., "Effect of Homocysteine-Lowering Therapy with Folic Acid, Vitamin	
	B ₁₂ , and Vitamin B ₆ on Clinical Outcome After Percutaneous Coronary Intervention," JAMA,	
	August 28, 2002, pp. 973-979, Vol. 288, No. 8.	1
66.	SHECHTER, MICHAEL, et al., "Oral Magnesium Supplementation Inhibits Platelet-Dependent	
ļ 	Thrombosis in Patients With Coronary Artery Disease," Am J Cardio., July 15, 1999, pp. 152-156,	
	Vol. 84.	
67.	SHECHTER, MICHAEL, et al., "Oral Magnesium Therapy Improves Endothelial Function in	
	Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102.	
68.	STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate	
	and Cobalamin Deficient Rats," Blood, 1994; pp. 118A, Vol 84, No. 10, Suppl. 1.	
69.	STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce	
	Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol.	
	332, No. 5.	
70.	STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic	ļ
	Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158.	
71.	STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with	
	Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996,	
	pp. 781-786, Vol. 347.	
72.	STIPANUK, MARTHA H., "Metabolism of Sulfur-Containing Amino Acids," Ann. Rev. Nutr., 1986,	
	pp. 179-209, Vol. 6.	
73.	TICE, JEFFREY A., et al., "Cost-effectiveness of Vitamin Therapy to Lower Plasma Homocysteine	
	Levels for the Prevention of Coronary Heart Disease: Effect of Grain Fortification and Beyond,"	
	JAMA, August 22/29, 2001, pp. 936-943, Vol. 286.	
	64. 65. 66. 67. 70. 71.	Cite term (book, magazine, journal, serials, empositure, catalog, etc.), date, page(st), volume-issue number(s), publisher, city and/or country where published 64. ROSSOUW, JACQUES E., et al., "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women" JAMA, July 17, 2002, pp. 321-333, Vol. 288, No. 3. 65. SCHNYDER, GUIDO, et al., "Effect of Homocysteine-Lowering Therapy with Folic Acid, Vitamin B ₁₂ , and Vitamin B ₆ on Clinical Outcome After Percutaneous Coronary Intervention," JAMA, August 28, 2002, pp. 973-979, Vol. 288, No. 8. 66. SHECHTER, MICHAEL, et al., "Oral Magnesium Supplementation Inhibits Platelet-Dependent Thrombosis in Patients With Coronary Artery Disease," Am J Cardio., July 15, 1999, pp. 152-156, Vol. 84. 67. SHECHTER, MICHAEL, et al., "Oral Magnesium Therapy Improves Endothelial Function in Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102. 68. STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate and Cobalamin Deficient Rats," Blood, 1994; pp. 118A, Vol 84, No. 10, Suppl. 1. 69. STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol. 332, No. 5. 70. STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158. 71. STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996, pp. 781-786, Vol. 347. 72. STIPANUK, MARTHA H., "Metabolism of Sulfur-Containing Amino Acids," Ann. Rev. Nutr., 1986, pp. 179-209, Vol. 6.

Examiner Signature	A	Date Considered	4/6/04

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Kn wn Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary of 6

Sheet 6

Application Numb r 10/635,928 **Filing Date** August 6, 2003 First Nam d Inv ntor Venkataraman **Group Art Unit Examiner Name** Attorney Docket Number 52761/286146

	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS					
	Examine r Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²		
		74.	UELAND, P.M. and REFSUM, H., "Plasma Homocysteine, A Risk Factor For Premature Vascular			
Micha			Disease. Plasma Levels in Healthy Person; During Pathologic Conditions and Drug Therapy Nord Med., 1989, pp. 293-308, Vol. 104, No. 11. (Abstract)			
\vdash		75.	VALAGUSSA, F., et al., "Dietary Supplementation With N-3 Polyunsaturated Fatty Acids and	 		
			Vitamin E After Myocardial Infarction: Results of the GISSI-Prevenzione Trial," The Lancet,	İ		
			August 7, 1999, pp. 447-455, Vol. 354.			
		76.	VAN DER KUY, et al., "Hydroxocobalamin, A Nitric Oxide Scavenger, In the Prophylaxis of			
			Migraine: An Open, Pilot Study," Cephalalgia Sept. 2002, pp. 513-519, Vol. 22, No. 7,.			
	77. VERHAAR, MARIANNE C., et al., "Effects of Oral Folic Acid Supplementation on Endothelia		VERHAAR, MARIANNE C., et al., "Effects of Oral Folic Acid Supplementation on Endothelial	1		
			Function in Familial Hypercholesterolemia," Circulation, July 27, 1999, pp. 335-338, Vol. 100.			
		78.	VIVANCO, N., et al., "Treatment of Anorexia Nervosa," Rev Med Chil, 1992, pp. 69-75, Vol. 120. (Abstract)			
		79.	WATERS, DAVID D., et al., "Effects of Hormone Replacement Therapy and Antioxidant Vitamin	<u> </u>		
			Supplements on Coronary Atherosclerosis in Postmenopausal Women," JAMA, November 20,			
			2002, pages 2432-3440, Vol 288, No. 19.			
•		80.	YANG, CHUN-YUH, "Calcium and Magnesium in Drinking Water and Risk of Death from			
m(4		Cerebrovascular Disease," Stroke, 1998, pp. 411-414, Vol. 29.			

	la de la companya della companya della companya de la companya della companya del			
Examiner	#1/1	Date	11/	<i>[</i>
Signature	4 <i>4</i> 4	Considered	14/6	<i> 0 (</i>
			'	